CLINICAL AND PARACLINICAL CHARACTERISTICS, TREATMENT OUTCOMES OF STRONGYLOIDIASIS AT HANOI MEDICAL UNIVERSITY HOSPITAL Introduction: Strongyloidiasis is a neglected
Main Article Content
Abstract
Introduction: Strongyloidiasis is a neglected tropical parasitic disease that affects a significant portion of the global population, particularly in developing countries. The disease can lead to severe complications and mortality if diagnosed late; therefore, increasing awareness and understanding of the disease is essential for timely diagnosis and treatment. Subjects and Methods: A cross-sectional descriptive study, combining retrospective and prospective analysis, was conducted on 40 patients with gastrointestinal strongyloidiasis at Hanoi Medical University Hospital from January 2021 to September 2023. Patients were selected using a convenience sampling method, including all eligible patients diagnosed with strongyloidiasis during the study period. Results: The disease primarily affects older adults (mean age 63.2 years) and is often associated with underlying conditions or immunosuppression. Common symptoms included abdominal pain (65%), diarrhea (47.5%), and nausea/vomiting (35%). Laboratory findings frequently showed eosinophilia (72.5%), hypoalbuminemia (72.5%), and anemia (67.5%). Diagnosis was based on ELISA testing (95% positive) and the detection of larvae in stool samples (37.5%). Treatment with a regimen of ivermectin and albendazole effectively improved symptoms and laboratory markers without significant side effects, with a 100% patient response rate.
Article Details
Keywords
Strongyloidiasis, ivermectin and albendazole, parasitic infection
References

2. Segarra-Newnham M. Manifestations, Diagnosis, and Treatment of Strongyloides stercoralis Infection. Ann Pharmacother. 2007 Dec 1;41(12):1992–2001.

3. Buonfrate D, Requena-Mendez A, Angheben A, Muñoz J, Gobbi F, Van Den Ende J, et al. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis. 2013 Feb 8;13(1):78.

4. Page W, Judd JA, Bradbury RS. The Unique Life Cycle of Strongyloides stercoralis and Implications for Public Health Action. Trop Med Infect Dis. 2018 Jun;3(2):53.

5. Buonfrate D, Sequi M, Mejia R, Cimino RO, Krolewiecki AJ, Albonico M, et al. Accuracy of Five Serologic Tests for the Follow up of Strongyloides stercoralis Infection. PLoS Negl Trop Dis. 2015 thg 2;9(2):e0003491.

6. Keiser PB, Nutman TB. Strongyloides stercoralis in the Immunocompromised Population. Clin Microbiol Rev. 2004 Jan;17(1): 208–17.

7. Czeresnia JM, Weiss LM. Strongyloides stercoralis. Lung. 2022 Apr 1;200(2):141–8.

8. Buonfrate D, Fittipaldo A, Vlieghe E, Bottieau E. Clinical and laboratory features of Strongyloides stercoralis infection at diagnosis and after treatment: a systematic review and meta-analysis. Clin Microbiol Infect. 2021 Nov 1;27(11):1621–8.

9. Ericsson CD, Steffen R, Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis Infection. Clin Infect Dis. 2001 Oct 1;33(7):1040–7.
